Clinical Trial Update: Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trials entry reports a Phase 1/2 study evaluating SX-682 in combination with apalutamide for metastatic castration-resistant prostate cancer, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)
• SX-682

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: RECRUITING